TwoStep Therapeutics Selected to Join JLABS

SAN CARLOS, Calif.--(BUSINESS WIRE)-- TwoStep Therapeutics (“TwoStep”), a biotechnology company developing innovative, first in class, multispecific targeted peptide conjugate therapies for solid tumors, is pleased to announce that it was selected to join Johnson & Johnson’s global incubator network, JLABS, as a resident at the MBC BioLabs site. TwoStep is a Stanford University spin-out launched in 2024, co-founded by Nobel Prize winner Carolyn Bertozzi, Jennifer Cochran, Ron Levy, and Caitlyn Miller, with seed investment of $8.7M to date led by NFX.

"Joining JLABS is an exciting development for our novel tumor-targeting peptide conjugate platform," said Caitlyn Miller PhD, CEO of TwoStep. "Through this membership, we hope to accelerate our research and development efforts, gain valuable insights, and ultimately bring our targeted therapies to cancer patients more efficiently.”

JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors.

About TwoStep Therapeutics

TwoStep Therapeutics is a biotechnology company developing a platform built around a unique tumor-targeting polyspecific integrin-binding peptide (PIP) that can selectively bind several targets that are highly expressed on solid tumors. This multi-targeting feature enables the agent’s broad applicability to a wide range of tumor types and patient populations, overcoming the limitations of single-antigen targeting approaches. The company leverages this technology to create a diverse pipeline of targeted cancer therapies for cytotoxic drug delivery, radioligand therapy, and immunotherapy.

More information: https://twosteptx.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20250325486398/en/

[email protected]

Source: TwoStep Therapeutics

You May Also Be Interested In

• Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
• Exclusive Networks Appoints Sergio Amodeo as Group Chief Financial Officer
• VivoPower Selects Global AI Industry Leader as Preferred AI Tenant for Lease of Norway Operational Data Center